News

Researchers from the University of Montréal Hospital Research Centre (CRCHUM) and the Cumming School of Medicine (CSM) at the University of Calgary have discovered a medication that can

As a result of the merger, Can-Fite’s ownership of OphthaliX, immediately post-merger, became approximately 8% of the outstanding shares. As part of the merger, Can-Fite cancelled OphthaliX’s prior

The companies have entered into a purchase agreement in which Cerecor will acquire TRx, including subsidiary Zylera Pharmaceuticals and its franchise of commercial medications led by Poly-Vi-Flor® (multivitamin

Trastuzumab, which is a monoclonal antibody, is the active substance in Ontruzant. This antibody binds with high affinity and specificity to the human epidermal growth factor receptor 2

Under the terms of the deal, the CUE Biologics platform will be leveraged to develop biologics engineered to selectively modulate disease-relevant T cell subsets for the treatment of

IONIS-JBI2-2.5Rx is designed to locally reduce the production of an undisclosed target in the gastrointestinal (GI) tract for the treatment of a GI autoimmune disease. Jansen will now

Hemlibra is a bispecific factor IXa- and factor X-directed antibody. The therapy which has been approved for both adults and children, functions by bridging other factors in the blood

The financing was led by Longitude Capital, and included participation from New Enterprise Associates (NEA), Novo Ventures and Sanofi Ventures. “Our mission is to develop potentially disease-modifying therapies

The multi-year strategic license agreement, initiated in October 2015, will encompass additional disease targets and expand the collaboration. Under the revised terms of the agreement, Arvinas is eligible